MEGIN
  • About us
    • About us
    • Meet the team
  • Our solution
    • MEG Maps™ powered by TRIUX™ neo
    • Book a MEG Maps™ Demo
  • News & Education
    • News
    • MEGIN Spotlights
    • MEGIN Masterclass
    • Abstracts and studies
  • Patients
  • Find a MEG site
    • Global
    • North America
  • Get in touch
    • Contact us
    • Book a MEG Maps™ Demo
Select Page
Westcan Proton Therapy Inc. will establish Canada’s first proton therapy facility in Edmonton, Alberta in coordination with MEGIN and other industry leading partners

Westcan Proton Therapy Inc. will establish Canada’s first proton therapy facility in Edmonton, Alberta in coordination with MEGIN and other industry leading partners

by MEGIN | Mar 20, 2024 | MEGIN News

EDMONTON, AB – WestCan Proton Therapy Inc. has announced their plans to invest in Canada’s first proton therapy treatment centre to be built in Edmonton. The centre will officially be named in honour of Ben Stelter, beloved six-year-old Edmonton Oilers super-fan and...
MEGIN proud to exhibit at 1st International Epilepsy Surgery Society Congress, Dubai, to strengthen awareness and partnerships in the region

MEGIN proud to exhibit at 1st International Epilepsy Surgery Society Congress, Dubai, to strengthen awareness and partnerships in the region

by MEGIN | Feb 7, 2024 | MEGIN News

MEGIN was delighted to recently exhibit at the 1st International Epilepsy Surgery Society Congress (IESS) in Dubai, January 19-21, 2024. The IESS event was endorsed by the International League Against Epilepsy (ILAE), in collaboration with the Epilepsy Surgery...
MEGIN is proud to enter into a strategic partnership with FIND Neuro, a Mass General Hospital backed organization

MEGIN is proud to enter into a strategic partnership with FIND Neuro, a Mass General Hospital backed organization

by MEGIN | Dec 2, 2023 | MEGIN News

MEGIN is delighted to announce a partnership with FIND Neuro, a disruptive start-up that reconstructs brain network maps to enable treatment of neurological diseases.  FIND Neuro originated at Mass General Hospital and was co-founded by Dr. Noam Peled (CEO), Prof...
MEGIN announces sale and installation of TRIUX™ neo to Simon Fraser University

MEGIN announces sale and installation of TRIUX™ neo to Simon Fraser University

by MEGIN | Oct 5, 2023 | MEGIN News

HELSINKI, FINLAND (October 5, 2023) – MEGIN is delighted to announce the sale and installation of our latest magnetoencephalography (MEG) technology, the TRIUX™ neo, to Simon Fraser University’s (SFU) core facility, ImageTech Lab. Located in British Columbia,...
Hiroshima University announces the sale of the first TRIUX™ neo in Japan

Hiroshima University announces the sale of the first TRIUX™ neo in Japan

by MEGIN | Jul 3, 2023 | MEGIN News

Hiroshima University Hospital press release – an announcement from our customer-partner   Hiroshima University Hospital established its Epilepsy Center in January 2014. The Epilepsy Center has since been responsible for providing tertiary medical care as part of the...
Fixel Institute expands care with new neuroimaging and clinical research suites

Fixel Institute expands care with new neuroimaging and clinical research suites

by MEGIN | Apr 27, 2023 | MEGIN News

A 15,000-square-foot neuroimaging suite that includes four high-tech imaging machines — including one of just three in the Southeast — opened Monday as the Norman Fixel Institute for Neurological Diseases at UF Health moves into a new phase of its growth. In addition...
« Older Entries
Next Entries »

Home
About us

MEG Maps™
Contact us
Subscribe to the newsletter

Insights & Education

News
MEGIN Spotlights
MEGIN Masterclass
Abstracts & studies

Patients

MEGIN China

Find a MEG site
Global
North America

Connect with us
  • Follow
  • Follow
  • Follow

Copyright 2026© – MEGIN
MEGIN’s new platform MEG Maps™ is powered by TRIUX™ neo and MEGreview™, which have 510(k) clearance from the US Food & Drug Administration (FDA) and are under EU MDR Notified body review, i.e. not available for commercial distribution in the EU area. For commercial distribution, please contact your local MEGIN representative. TRIUX™ neo is intended to non-invasively record brain activity, and when interpreted by trained physicians, to help localize these active areas. All other applications are scientific research in nature. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician
.